CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful faithfully but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the last few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set out what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire employment interview which I came away with a bad opinion of the company.

Irony of irony, my poor impression of the business has grown steadily, though the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the know-how and also linked intellectual property from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) plus the very first new drug program endorsement ($5 million), and also royalty payments of 5 percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and many therapies, it’s this single treatments as well as a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its website (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple illness types, multiple delivering presentations in addition to multiple publications.

Might all of it be smoke and mirrors? That is a question I have been asking myself with the very start of my interest in this business. Judging by the multiples of thousands of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a classic battleground, or some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Published
Categorized as Health

Leave a comment

Your email address will not be published. Required fields are marked *